CELLINK is the world-leading bioconvergence company creating the future of medicine by providing technologies, products and services to create, understand, and master biology.

In 2016, we commercialized the world’s first universal bioink - an innovation 8 years in the making - which spurred our rapid rise to becoming the world’s leading bioprinting company. Fast-forward to 2021, after five successful acquisitions and several high-profile product launches, we are much more than a bioprinting company. We have embraced the emerging bio-convergence revolution, which is leveraging synergistic breakthroughs in the life sciences and technology to meet the world’s growing healthcare needs. By combining advances in biology, engineering, big data and AI, we are now the top bio-convergence company in the world, creating the future of medicine.